Symbols / ATRA
ATRA Chart
About
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 33.60M |
| Enterprise Value | 33.60M | Income | 23.40M | Sales | 151.93M |
| Book/sh | -5.08 | Cash/sh | 1.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 38 | IPO | — |
| P/E | 1.63 | Forward P/E | 39.94 | PEG | — |
| P/S | 0.22 | P/B | -0.92 | P/C | — |
| EV/EBITDA | 0.75 | EV/Sales | 0.22 | Quick Ratio | 0.86 |
| Current Ratio | 1.02 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 2.86 | EPS next Y | 0.12 | EPS Growth | — |
| Revenue Growth | -91.40% | Earnings | 2026-03-05 | ROA | 30.86% |
| ROE | — | ROIC | — | Gross Margin | 46.76% |
| Oper. Margin | -102.72% | Profit Margin | 15.40% | Shs Outstand | 7.21M |
| Shs Float | 4.63M | Short Float | 4.75% | Short Ratio | 0.42 |
| Short Interest | — | 52W High | 19.14 | 52W Low | 4.13 |
| Beta | -0.42 | Avg Volume | 296.43K | Volume | 111.42K |
| Target Price | $5.00 | Recom | Hold | Prev Close | $4.21 |
| Price | $4.66 | Change | 10.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$4.66
Latest analyst target
3. DCF / Fair value
$-161.97
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.66
Low
$4.00
High
$6.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-13 | down | Canaccord Genuity | Buy → Hold | $6 |
| 2025-12-19 | main | Canaccord Genuity | Buy → Buy | $25 |
| 2025-03-11 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2025-01-22 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-17 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2024-12-20 | init | Rodman & Renshaw | — → Buy | $25 |
| 2024-11-13 | main | Canaccord Genuity | Buy → Buy | $21 |
| 2024-08-21 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-16 | up | Mizuho | Neutral → Outperform | $18 |
| 2024-08-13 | main | Canaccord Genuity | Buy → Buy | $13 |
| 2024-07-17 | main | Goldman Sachs | Sell → Sell | $11 |
| 2024-05-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-01 | main | Stifel | Hold → Hold | $2 |
| 2023-11-10 | main | Goldman Sachs | Sell → Sell | $1 |
| 2023-11-09 | down | Evercore ISI Group | Outperform → In-Line | — |
| 2023-11-09 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2023-11-09 | down | Mizuho | Buy → Neutral | $1 |
| 2023-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2023-08-21 | main | Citigroup | Sell → Sell | $1 |
| 2023-08-09 | reit | EF Hutton | Buy → Buy | $25 |
- Biotech Atara pushes $9M payment to 2028, grants 400,000-share warrant - Stock Titan Mon, 23 Feb 2026 13
- ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits Mon, 12 Jan 2026 08
- Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant - TipRanks Mon, 23 Feb 2026 14
- Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance hu, 25 Sep 2025 07
- Atara Biotherapeutics stock plunges after FDA rejects cancer therapy - Investing.com Mon, 12 Jan 2026 08
- Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement - GuruFocus Mon, 23 Feb 2026 17
- Atara (NASDAQ: ATRA) extends $9M HCRx payment and grants 400,000-share warrant - Stock Titan Mon, 23 Feb 2026 13
- With Atara Biotherapeutics Stock Surging, Have You Considered The Downside? - Trefis Sat, 20 Dec 2025 08
- There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues - simplywall.st Mon, 16 Feb 2026 08
- Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire Wed, 12 Nov 2025 08
- $ATRA stock is down 13% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha Sun, 30 Nov 2025 08
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - PR Newswire hu, 22 Jan 2026 08
- Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks hu, 08 Jan 2026 08
- We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st ue, 08 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 80554 | 489019.0 | — | Sale at price 6.07 per share. | PANACEA INNOVATION LTD | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-12 00:00:00 | I |
| 1 | 48737 | 5.0 | — | Conversion of Exercise of derivative security at price 0.00 per share. | PANACEA VENTURE | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-28 00:00:00 | I |
| 2 | 2915 | 38437.0 | — | Sale at price 13.19 per share. | NGUYEN ANHCO T | Chief Executive Officer | — | 2025-11-17 00:00:00 | D |
| 3 | 1804 | 23788.0 | — | Sale at price 13.19 per share. | GRANT-HUERTA YANINA | Officer | — | 2025-11-17 00:00:00 | D |
| 4 | 2958 | 34360.0 | — | Sale at price 11.61 - 11.62 per share. | NGUYEN ANHCO T | Chief Executive Officer | — | 2025-08-18 00:00:00 | D |
| 5 | 1809 | 21009.0 | — | Sale at price 11.61 per share. | GRANT-HUERTA YANINA | Officer | — | 2025-08-18 00:00:00 | D |
| 6 | 19335 | 186372.0 | — | Purchase at price 9.64 per share. | PANACEA INNOVATION LTD | Beneficial Owner of more than 10% of a Class of Security | — | 2025-07-17 00:00:00 | I |
| 7 | 7828 | — | — | Stock Award(Grant) at price 0.00 per share. | GALLAGHER CAROL GILTNER | Director | — | 2025-06-10 00:00:00 | D |
| 8 | 7828 | — | — | Stock Award(Grant) at price 0.00 per share. | TOUCHON PASCAL | Director | — | 2025-06-10 00:00:00 | D |
| 9 | 7828 | — | — | Stock Award(Grant) at price 0.00 per share. | FUST MATTHEW K. | Director | — | 2025-06-10 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -75.75M | -266.00M | -272.50M | -331.12M |
| TotalUnusualItems | 0.00 | 50.24M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 50.24M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -85.40M | -276.13M | -228.30M | -340.14M |
| ReconciledDepreciation | 5.05M | 4.83M | 5.65M | 9.35M |
| ReconciledCostOfRevenue | 21.01M | 8.89M | 0.00 | |
| EBITDA | -75.75M | -266.00M | -222.26M | -331.12M |
| EBIT | -80.80M | -270.83M | -227.92M | -340.46M |
| NetInterestIncome | -2.50M | 141.00K | 2.69M | 367.00K |
| InterestExpense | 4.62M | 5.29M | 373.00K | |
| InterestIncome | 2.11M | 5.43M | 3.06M | 367.00K |
| NormalizedIncome | -85.40M | -276.13M | -278.54M | -340.14M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -85.40M | -276.13M | -228.30M | -340.14M |
| TotalExpenses | 212.38M | 284.58M | 344.09M | 360.80M |
| TotalOperatingIncomeAsReported | -83.44M | -276.01M | -280.51M | -340.46M |
| DilutedAverageShares | 7.49M | 4.24M | 4.08M | 3.75M |
| BasicAverageShares | 7.49M | 4.24M | 4.08M | 3.75M |
| DilutedEPS | -11.41 | -65.19 | -56.00 | -90.75 |
| BasicEPS | -11.41 | -65.19 | -56.00 | -90.75 |
| DilutedNIAvailtoComStockholders | -85.40M | -276.13M | -228.30M | -340.14M |
| NetIncomeCommonStockholders | -85.40M | -276.13M | -228.30M | -340.14M |
| NetIncome | -85.40M | -276.13M | -228.30M | -340.14M |
| NetIncomeIncludingNoncontrollingInterests | -85.40M | -276.13M | -228.30M | -340.14M |
| NetIncomeContinuousOperations | -85.40M | -276.13M | -228.30M | -340.14M |
| TaxProvision | -12.00K | 15.00K | 12.00K | 46.00K |
| PretaxIncome | -85.42M | -276.11M | -228.29M | -340.10M |
| OtherIncomeExpense | 528.00K | -246.00K | 49.54M | |
| OtherNonOperatingIncomeExpenses | 528.00K | -246.00K | -700.00K | |
| SpecialIncomeCharges | 0.00 | 50.24M | 0.00 | |
| GainOnSaleOfPPE | 0.00 | 50.24M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -2.50M | 141.00K | 2.69M | 367.00K |
| TotalOtherFinanceCost | -367.00K | |||
| InterestExpenseNonOperating | 4.62M | 5.29M | 373.00K | |
| InterestIncomeNonOperating | 2.11M | 5.43M | 3.06M | 367.00K |
| OperatingIncome | -83.44M | -276.01M | -280.51M | -340.46M |
| OperatingExpense | 191.37M | 275.69M | 344.09M | 360.80M |
| ResearchAndDevelopment | 151.48M | 224.78M | 272.53M | 282.00M |
| SellingGeneralAndAdministration | 39.89M | 50.91M | 71.55M | 78.80M |
| GeneralAndAdministrativeExpense | 39.89M | 50.91M | 71.55M | 78.80M |
| OtherGandA | 39.89M | 50.91M | 71.55M | 78.80M |
| GrossProfit | 107.93M | -313.00K | 63.57M | |
| CostOfRevenue | 21.01M | 8.89M | 0.00 | |
| TotalRevenue | 128.94M | 8.57M | 63.57M | 20.34M |
| OperatingRevenue | 128.94M | 8.57M | 63.57M | 20.34M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 5.86M | 4.26M | 3.84M | 3.67M |
| ShareIssued | 5.86M | 4.26M | 3.84M | 3.67M |
| TotalDebt | 43.83M | 57.87M | 71.70M | 28.27M |
| TangibleBookValue | -97.28M | -99.23M | 126.64M | 279.61M |
| InvestedCapital | -97.28M | -99.23M | 126.64M | 279.61M |
| WorkingCapital | -69.68M | -40.36M | 216.16M | 278.83M |
| NetTangibleAssets | -97.28M | -99.23M | 126.64M | 279.61M |
| CapitalLeaseObligations | 43.83M | 57.87M | 71.70M | 28.27M |
| CommonStockEquity | -97.28M | -99.23M | 126.64M | 279.61M |
| TotalCapitalization | -97.28M | -99.23M | 126.64M | 279.61M |
| TotalEquityGrossMinorityInterest | -97.28M | -99.23M | 126.64M | 279.61M |
| StockholdersEquity | -97.28M | -99.23M | 126.64M | 279.61M |
| GainsLossesNotAffectingRetainedEarnings | 8.00K | -204.00K | -2.07M | -368.00K |
| OtherEquityAdjustments | 8.00K | -204.00K | -2.07M | -368.00K |
| RetainedEarnings | -2.05B | -1.97B | -1.69B | -1.46B |
| AdditionalPaidInCapital | 1.96B | 1.87B | 1.82B | 1.74B |
| CapitalStock | 1.00K | 0.00 | 10.00K | 9.00K |
| CommonStock | 1.00K | 0.00 | 10.00K | 9.00K |
| TotalLiabilitiesNetMinorityInterest | 206.38M | 264.74M | 249.78M | 188.51M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 71.81M | 122.51M | 170.86M | 82.73M |
| OtherNonCurrentLiabilities | 41.89M | 39.25M | 35.80M | 1.50M |
| NonCurrentDeferredLiabilities | 0.00 | 37.56M | 77.00M | 55.71M |
| NonCurrentDeferredRevenue | 0.00 | 37.56M | 77.00M | 55.71M |
| LongTermDebtAndCapitalLeaseObligation | 29.91M | 45.69M | 58.06M | 25.52M |
| LongTermCapitalLeaseObligation | 29.91M | 45.69M | 58.06M | 25.52M |
| LongTermProvisions | 30.24M | |||
| CurrentLiabilities | 134.57M | 142.23M | 78.92M | 105.79M |
| CurrentDeferredLiabilities | 95.09M | 77.83M | 8.00M | 40.76M |
| CurrentDeferredRevenue | 95.09M | 77.83M | 8.00M | 40.76M |
| CurrentDebtAndCapitalLeaseObligation | 13.92M | 12.18M | 13.64M | 2.75M |
| CurrentCapitalLeaseObligation | 13.92M | 12.18M | 13.64M | 2.75M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.59M | 11.52M | 17.66M | 25.15M |
| PayablesAndAccruedExpenses | 18.98M | 40.70M | 39.62M | 37.12M |
| CurrentAccruedExpenses | 14.61M | 37.01M | 32.75M | 19.75M |
| Payables | 4.37M | 3.68M | 6.87M | 17.37M |
| AccountsPayable | 4.37M | 3.68M | 6.87M | 17.37M |
| TotalAssets | 109.10M | 165.50M | 376.42M | 468.13M |
| TotalNonCurrentAssets | 44.20M | 63.63M | 81.34M | 83.51M |
| OtherNonCurrentAssets | 3.10M | 4.84M | 7.02M | 3.57M |
| NetPPE | 41.10M | 58.79M | 74.32M | 79.94M |
| AccumulatedDepreciation | -17.31M | -15.87M | -12.42M | -28.74M |
| GrossPPE | 58.41M | 74.66M | 86.74M | 108.68M |
| Leases | 930.00K | 904.00K | 875.00K | 50.14M |
| ConstructionInProgress | 0.00 | 158.00K | 32.00K | 6.33M |
| OtherProperties | 54.25M | 70.47M | 82.82M | 40.22M |
| MachineryFurnitureEquipment | 3.23M | 3.12M | 3.02M | 11.99M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 64.89M | 101.87M | 295.08M | 384.62M |
| OtherCurrentAssets | 10.12M | 6.18M | 10.31M | 12.37M |
| RestrictedCash | 146.00K | 146.00K | 146.00K | 194.00K |
| PrepaidAssets | 12.37M | |||
| Inventory | 10.65M | 9.71M | 1.59M | 0.00 |
| WorkInProcess | 9.69M | 7.37M | 372.00K | 0.00 |
| RawMaterials | 964.00K | 2.33M | 1.21M | 0.00 |
| Receivables | 1.48M | 34.11M | 40.22M | 986.00K |
| AccountsReceivable | 1.48M | 34.11M | 40.22M | 986.00K |
| CashCashEquivalentsAndShortTermInvestments | 42.50M | 51.73M | 242.82M | 371.07M |
| OtherShortTermInvestments | 17.47M | 25.88M | 149.88M | 264.98M |
| CashAndCashEquivalents | 25.03M | 25.84M | 92.94M | 106.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -68.96M | -194.20M | -274.62M | -231.10M |
| RepaymentOfDebt | -892.00K | -947.00K | -518.00K | -254.00K |
| IssuanceOfCapitalStock | 59.95M | 2.14M | 21.89M | 98.70M |
| CapitalExpenditure | -246.00K | -1.22M | -4.19M | -10.58M |
| InterestPaidSupplementalData | 685.00K | 447.00K | 335.00K | 32.00K |
| IncomeTaxPaidSupplementalData | 24.00K | 2.00K | 19.00K | 15.00K |
| EndCashPosition | 25.18M | 25.99M | 93.09M | 107.48M |
| BeginningCashPosition | 25.99M | 93.09M | 107.48M | 201.80M |
| ChangesInCash | -811.00K | -67.10M | -14.39M | -94.32M |
| FinancingCashFlow | 59.28M | 2.01M | 53.08M | 103.94M |
| CashFlowFromContinuingFinancingActivities | 59.28M | 2.01M | 53.08M | 103.94M |
| NetOtherFinancingCharges | -7.00K | -107.00K | 29.79M | -1.26M |
| ProceedsFromStockOptionExercised | 230.00K | 928.00K | 1.92M | 6.76M |
| NetCommonStockIssuance | 59.95M | 2.14M | 21.89M | 98.70M |
| CommonStockIssuance | 59.95M | 2.14M | 21.89M | 98.70M |
| NetIssuancePaymentsOfDebt | -892.00K | -947.00K | -518.00K | -254.00K |
| NetLongTermDebtIssuance | -892.00K | -947.00K | -518.00K | -254.00K |
| LongTermDebtPayments | -892.00K | -947.00K | -518.00K | -254.00K |
| InvestingCashFlow | 8.62M | 123.87M | 202.96M | 22.26M |
| CashFlowFromContinuingInvestingActivities | 8.62M | 123.87M | 202.96M | 22.26M |
| NetInvestmentPurchaseAndSale | 8.87M | 125.06M | 112.38M | 32.84M |
| SaleOfInvestment | 28.54M | 208.71M | 292.97M | 333.97M |
| PurchaseOfInvestment | -19.66M | -83.65M | -180.59M | -301.13M |
| NetPPEPurchaseAndSale | -246.00K | -1.20M | 90.57M | -10.58M |
| SaleOfPPE | 0.00 | 25.00K | 94.77M | 0.00 |
| PurchaseOfPPE | -246.00K | -1.22M | -4.19M | -10.58M |
| OperatingCashFlow | -68.72M | -192.98M | -270.43M | -220.52M |
| CashFlowFromContinuingOperatingActivities | -68.72M | -192.98M | -270.43M | -220.52M |
| ChangeInWorkingCapital | -30.96M | 15.34M | -61.47M | 52.58M |
| ChangeInOtherWorkingCapital | -20.30M | 30.39M | -11.47M | 35.22M |
| ChangeInOtherCurrentLiabilities | -24.02M | -1.43M | -5.59M | -750.00K |
| ChangeInOtherCurrentAssets | -1.21M | 1.32M | 1.57M | 6.46M |
| ChangeInPayablesAndAccruedExpense | -13.62M | -12.93M | -5.16M | 11.40M |
| ChangeInAccruedExpense | -14.31M | -9.80M | 4.05M | 2.33M |
| ChangeInPayable | 687.00K | -3.13M | -9.21M | 9.07M |
| ChangeInAccountPayable | 687.00K | -3.13M | -9.21M | 9.07M |
| ChangeInPrepaidAssets | 8.18M | |||
| ChangeInInventory | -4.43M | -8.12M | -1.59M | 0.00 |
| ChangeInReceivables | 32.63M | 6.11M | -39.23M | 264.00K |
| ChangesInAccountReceivables | 32.63M | 6.11M | -39.23M | 264.00K |
| OtherNonCashItems | 15.83M | 16.80M | 9.06M | 2.06M |
| StockBasedCompensation | 27.00M | 45.39M | 53.84M | 53.87M |
| AmortizationOfSecurities | -240.00K | 792.00K | 1.02M | 1.77M |
| DepreciationAmortizationDepletion | 5.05M | 4.83M | 5.65M | 9.35M |
| DepreciationAndAmortization | 5.05M | 4.83M | 5.65M | 9.35M |
| OperatingGainsLosses | -50.24M | 21.00K | ||
| GainLossOnSaleOfPPE | 0.00 | -50.24M | 0.00 | |
| NetIncomeFromContinuingOperations | -85.40M | -276.13M | -228.30M | -340.14M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ATRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|